Bioaffinity Technologies, Inc. (BIAF) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bioaffinity Technologies, Inc. on November 14, 2024. The filing serves to disseminate a press release containing financial information for the quarter ended September 30, 2024. The company is an emerging growth company incorporated in Delaware, with its principal executive offices in San Antonio, Texas.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing explicitly references a press release (Exhibit 99.1) as the source for these figures but does not embed the data within the 8-K text itself.
Material Changes
No material changes versus the prior comparable period are detailed in the text of this filing. The document functions solely as a notification that financial results for the quarter ended September 30, 2024, have been issued.
Guidance, Outlook, and Risks
The filing includes standard legal disclaimers stating that the information in Item 2.02 and the attached press release shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other SEC filings. No specific guidance, management commentary, risks, or contingencies are described in the text provided.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 14, 2024) for actual financial figures for the quarter ended September 30, 2024.
- Verify the company's status as an emerging growth company and its implications for financial reporting standards.
- Confirm the trading status of Common Stock (BIAF) and Tradeable Warrants (BIAFW) on The Nasdaq Stock Market LLC.
- Note that the financial data in this 8-K is not incorporated by reference into future filings.